Good News: Human Evidence. A Recognized Target. A Reason for Hope.

A newly published case report out of Germany has given us something incredibly meaningful:
human evidence that the defining genetic fusion in Ewing sarcoma can be targeted with a vaccine—and the immune system can learn to recognize it.

Researchers created a vaccine using small pieces of the EWSR1–FLI1 fusion, the genetic abnormality that drives most Ewing sarcomas. Before vaccination, the patient had no detectable immune response against those fusion peptides. After vaccination, researchers found a strong, durable T-cell response that persisted for more than two years.

Why does that matter to Little Warrior Foundation?
Because this is the same fundamental vulnerability we are trying to exploit with SupraVax.
There is an important difference, though.

The German team used a traditional peptide vaccine. SupraVax is being developed using replicating RNA (repRNA) in a Nanostructured Lipid Carrier (NLC). Rather than simply giving the immune system pieces of the target, our goal is to get cells to produce the target antigen internally—giving the immune system the opportunity to mount a broader response, including the kind of killer T cells we hope can recognize and destroy Ewing sarcoma cells.
Think of this new study as an important piece of the puzzle:

Is EWSR1–FLI1 a promising vaccine target?

This case provides encouraging human evidence that it is.

Can the human immune system be taught to recognize it?

In this patient, yes.

Can we use a next-generation RNA vaccine platform to create an even stronger, more effective anti-tumor response?

That’s what we’re working to find out with SupraVax.

There is still a long road between an immune response in one patient and a vaccine proven to prevent or treat Ewing sarcoma. This study does not prove that vaccination caused the patient's prolonged disease control, but it adds a bit more science-backed reasons to believe!
In research, progress often comes one piece of evidence at a time.

And this is a piece of evidence we are very, very happy to see.

For every warrior. For every family. And for a future where relapse doesn't have to be the fear that follows Ewing families home.

We know we've asked for your patience, when you have every reason to be impatient. SupraVax will be presented to the FDA for approval soon. In the meantime, manufacturing moves full steam ahead.

With hearts full of hope, swords up!